Healthcare RCM Consulting for Infectious Disease Practices

An RCM company helps manage the financial workflow between delivering care and receiving payment. For infectious disease practices, that may include charge capture, coding review, eligibility and authorization, claim submission, rejection clearing, denial appeals, payment reconciliation, contract review, and A/R follow-up. Consulting may also identify where documentation, workflow, payer requirements, or operational decisions are causing revenue to be delayed, reduced, or left uncollected.

Healthcare RCM consulting for infectious disease practices examines how clinical services become billable revenue. The review can cover office visits, hospital consults, infusion administration, drug claims, OPAT, documentation, coding, authorization, payer contracts, denials, underpayments, and aging A/R. The goal is to identify the source of revenue leakage and provide a prioritized, practical plan suited to the practice’s own services, systems, agreements, and financial information.

Yes. Infusion and OPAT create additional workflow and reimbursement requirements beyond cognitive visits. Consulting can review eligibility, medical versus pharmacy benefit handling, prior authorization, drug acquisition, administration charges, documentation, coding, claim submission, denials, payment reconciliation, and A/R follow-up. The review helps practices understand whether the workflow supports complete and accurate billing and where unreimbursed drug or administration costs may arise.

Revenue leakage can occur through under-leveled visits, missed drug or administration charges, documentation gaps, authorization problems, incorrect benefit handling, payer underpayments, contract noncompliance, and unresolved balances. Reporting by payer, service line, provider, and claim status can reveal patterns. A detailed review then traces those patterns back to documentation, charge capture, coding, workflow, contract, or follow-up issues.

It can. Denial support may categorize denials by root cause, identify recurring issues, and prepare payer-specific appeals supported by clinical documentation. Infectious disease denial categories can include drug and administration coding, missing authorization, medical versus pharmacy benefit confusion, and under-documented consults. Findings can also be shared with clinical, coding, and front-office teams so corrective changes address the source rather than only the individual claim.

Yes. Payment reconciliation can compare payer payments with expected reimbursement for drug, administration, and E/M claims. The review may identify short-pays, incorrect fee schedule application, unit mismatches, NDC mismatches, or other differences. Contract and coverage agreement reviews can also examine whether reimbursement aligns with documented terms, including arrangements involving hospital coverage, stewardship, infusion, and consult services.

The appropriate information depends on the review’s scope, but useful materials may include workflow descriptions, payer and service-line reports, claims data, denial categories, payment records, aging A/R, contracts, authorization processes, and documentation or coding practices. GrowInfectiousDisease emphasizes applying the practice’s own numbers rather than relying on generalized rates or margins, and it remains explicit when information is unavailable or practice-specific.

GrowInfectiousDisease is a free resource hub focused on the economics and operations of independent infectious disease practices. Its materials explain revenue-cycle issues and provide browser-based tools, practical guidance, and economic models. The service catalog also describes consulting and support concepts such as claims management, denials, authorization, payment reconciliation, and A/R recovery. Practices should evaluate the appropriate level of hands-on support for their own systems and needs.